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The growth of axons is an intricately regulated process involving intracellular signaling cascades and gene transcription. We had previ-
ously shown that the stimulus-dependent transcription factor, serumresponse factor (SRF), plays a critical role in regulatingaxongrowth
in the mammalian brain. However, the molecular mechanisms underlying SRF-dependent axon growth remains unknown. Here we
report that SRF is phosphorylated and activated by GSK-3 to promote axon outgrowth in mouse hippocampal neurons. GSK-3 binds to
and directly phosphorylates SRF on a highly conserved serine residue. This serine phosphorylation is necessary for SRF activity and for
its interaction with MKL-family cofactors, MKL1 andMKL2, but not with TCF-family cofactor, ELK-1. Axonal growth deficits caused by
GSK-3 inhibition could be rescued by expression of a constitutively active SRF. The SRF target gene and actin-binding protein, vinculin,
is sufficient to overcome the axonal growth deficits of SRF-deficient and GSK-3-inhibited neurons. Furthermore, short hairpin RNA-
mediated knockdownof vinculin also attenuated axonal growth. Thus, our findings reveal a novel phosphorylation and activation of SRF
by GSK-3 that is critical for SRF-dependent axon growth in mammalian central neurons.
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Introduction
In developingCNS, neurite initiation and outgrowth are essential
to ensure proper development of axons and to establish func-
tional neuronal connections (Zhou and Snider, 2006; Polleux
and Snider, 2010). SRF is aMADS-domain-containing transcrip-
tion factor that is critical for expression of several stimulus-
activated and cytoskeletal genes, including actin, vinculin, c-fos,
and egr-1 (Treisman, 1987; Miano, 2003; Ramanan et al., 2005).
Recent studies, including our own, using conditional knock-out
mice have shown that SRF plays a critical cell-autonomous role in
axonal growth both in vitro and in vivo (Kno¨ll et al., 2006; Lu and
Ramanan, 2011). Despite these findings, the post-translational
mechanisms by which SRF activity is regulated in neurons as well
as the downstream target genes that are critical for mediating
axon growth remain poorly understood.
Among the intracellular signalingmechanisms, GSK-3 signal-
ing has gained particular prominence in the regulation of both
neuronal polarity and axon outgrowth. GSK-3 is a serine/threo-
nine kinase first characterized for its role in glycogenmetabolism
(Cohen and Frame, 2001; Doble and Woodgett, 2003). Recent
studies, using both pharmacological and genetic approaches to
block GSK-3 activity, have shown that GSK-3 is necessary for
axon growth (Kim et al., 2006; Garrido et al., 2007; Alabed et al.,
2010; Hur et al., 2011). Complete inactivation of GSK-3 kinases
resulted in strong inhibition of axon growth, which may be the
result of dampenedmicrotubule dynamics (Kim et al., 2006; Ala-
bed et al., 2010). A widely studied mechanism by which GSK-3
regulates axon growth is by regulating microtubule reorganiza-
tion in the growth cone (Zhou et al., 2004; Yoshimura et al., 2005;
Kim et al., 2006). Despite these advances, whether GSK-3 acti-
vates transcriptional mechanisms critical for axon outgrowth re-
mains known. It is possible that axonal growth deficits caused by
inhibition of GSK-3 activity could result, at least in part, from
inhibition of transcriptional programs critical for axon growth.
In this study, we identify SRF as a novel transcriptional target
of GSK-3 and show that phosphorylation of SRF by GSK-3 is
necessary for SRF transcriptional activity. Specifically, this phos-
phorylation is required for SRF interaction with the myocardin
family cofactors, MKL1 andMKL2, but not with the TCF-family
cofactor, ELK1. In addition, blockade of GSK-3 activity attenu-
ates SRF target gene expression. Furthermore, SRF is sufficient to
promote axonal growth in the absence of GSK-3 signaling. We
also found that SRF is essential for filopodia formation, a neces-
sary first step for Stage 1 axon growth. Finally, we demonstrate
that vinculin (VCL), an actin-binding protein and previously
identified SRF target gene, can promote axonal growth in SRF-
deficient and GSK-3 inhibited neurons. Together, our findings
suggest that SRF is likely a critical transcription factor for GSK-
3-mediated axonal growth.
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Materials andMethods
Animals. The generation of Srf-f/f mice was previously described (Ra-
manan et al., 2005). These mice were bred to Nestin-Cre transgenic mice
(The Jackson Laboratory). Srf-NestinCKO mutant mice were obtained
from crosses between Srf-f/f and Srf-f/;NestinCre double heterozy-
gotes. Mice of either sex were used for preparing neuronal cultures. All
experiments were approved by Animals Studies Committee, Division of
Comparative Medicine, Washington University School of Medicine.
Immunohistochemistry. Immunohistochemistry was performed as
previously described (Ramanan et al., 2005; Lu and Ramanan, 2011).
Briefly, P0.5 animals were fixed by transcardial perfusion. The brains
were cryopreserved in 30% sucrose, frozen, and stored at 80°C until
use. For staining, 12 to 16 m cryosections were made and incubated
in blocking/permeabilization solution containing 3% goat serum 
0.3% Triton-X in PBS. The antibodies used are listed below (see
Immunocytochemistry).
Neuronal culture, transfection, and pharmacology. Hippocampus and
neocortex were dissected from postnatal 0.5 d (P0.5) mice, digested with
papain for 30 min at 30°C, and dissociated with micropipette tips in
culturing medium (Neurobasal-A medium supplemented with 0.5 mM
L-glutamine and B27 supplements, Invitrogen). Neurons were then
plated on coverglasses (Glaswarenfabrik Karl Hecht) coated with poly-
D-lysine or poly-D-lysine and laminin at a density of 125 neurons/
mm2. Neuronal cultures were incubated at 37°C with 5% CO2. After
neurons attached to poly-D-lysine coverglass (15min after plating), the
medium was gently exchanged to new neuronal culturing medium sup-
plemented with 33 U/ml penicillin/streptomycin. After 4 d in culture,
neurons were fixed with 4%PFA/4% sucrose in PBS for 20min. Neurons
were transfected using Amaxa Nucleofection (Lonza) according to the
manufacturer’s instructions. A total of 3–5g of DNAwas used for each
transfection. The inhibitors, 6-bromoindirubin-3-acetoxime (500 nM,
Calbiochem) or lithium chloride (2 mM, Sigma-Aldrich) were directly
added to neuronal culture medium 15 min after plating at the initial
medium exchange.
Phalloidin staining. Neuronal cultures were rinsed in PBS and fixed
in 1–2% paraformaldehyde in PBS for 15 min at room temperature;
0.1 M glycine was added to quench excess aldehyde for 5 min. The
cultures were then permeabilized with 0.1% Triton X-100 in PBS for
5 min and incubated in 1:125 dilution of rhodamine-phalloidin (Cy-
toskeleton) for 15 min. The cultures were washed with PBS for 5 min,
thrice, and mounted on slides.
Immunocytochemistry and quantification of axon growth.Neuronswere
fixed at different time points. Fixed neurons on coverglass were blocked
and permeabilized with blocking solution (10% goat serum and 0.1%
Triton-X in PBS) for 30minwith gentle rocking, incubated with primary
antibody diluted in blocking solution for 45 min with gentle rocking,
washed with PBS for 2 min thrice, incubated with secondary antibody
diluted in blocking solution for 25 min with gentle rocking, and then
washed with PBS beforemounting with vector shieldmountingmedium
supplemented with DAPI (Vector Laboratories). The following primary
antibodies were used: anti-SRF (1:2000, Santa Cruz Biotechnology),
anti-MAP2 (1:1000, Sigma), anti--III tubulin (Tuj1, 1:1000, Sigma),
anti-Tau (1:1000, Millipore), anti-pan sodium channel, clone K58/35
(1:500, Sigma), anti-HA (1:1000, Sigma), and anti-Myc (1:100, Develop-
mental Hybridoma). The secondary antibodies were AlexaFluor-488 and
-594–conjugated anti-mouse or anti-rabbit at 1:1000 dilution (Invitrogen).
Only live neurons, based on the characteristic uncondensed DAPI staining,
were chosen for analysis in a double-blinded manner. Neurite growth was
analyzed by measuring the length of the longest neurite of Tuj1-positive
neurons. ImageJ softwareandNeuronJplug-inwereused tomeasureneurite
length, growth cone and cell soma areas, etc.
Immunoprecipitation. P0.5 mouse brains were dissected and homoge-
nized in ice-cold protein extraction buffer: 20mMHEPES, 125mMNaCl,
5 mM MgCl2, 0.2 mM EDTA, pH 8, 1 mM EGTA, 1 mM NaF, 5 mM DTT,
glycerol, NP40, protease inhibitors (Roche), and phosphatase inhibitors
(Roche). The homogenate was centrifuged at 12,000  g at 4°C for 10
min, precleared with beads, and supernatant was quantitated with Brad-
ford reagent (Fermentas). A total of 10 l of protein-A magnetic beads
was washed with 0.1% BSA in PBS twice and 3 times with PBS. The
antibody of choice (1–3 g) was conjugated to the beads by incubating
with the beads on a rotary shaker for 1–3 h. The beads were then washed
3 times with PBS; 3 mg of total protein was mixed with the antibody-
conjugated beads and incubated overnight at 4°C on the rotary shaker.
The following day, the magnetic beads were washed with protein extrac-
tion buffer 3 times. The beads were boiled with Laemmli sample buffer
before separation by SDS-PAGE electrophoresis. In addition to epitope
antibodies listed above, GSK-3/ antibody (Santa Cruz Biotechnol-
ogy), GSK-3, and GSK-3 pSer9 antibody (Cell Signaling Technology)
were also used.
Site-directed mutagenesis. Site-specific mutants were generated using
QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to
themanufacturer’s instructions. Briefly, complementary primers of40
bp were designed with the mutation site in the middle of the sequence
and 25 ng of template DNA was used along with 25 pmol each of the
mutant primers. A 2 min extension for every 1 kb of template was used.
PCR for a total of 18 cycles was set as follows: 95°C for 3 min; 68°C for
(X-kb  2 min); 18 cycles; 72°C for 10 min; end at 4°C. The reaction
mixture was digested with DpnI to remove template DNA and ligation
setwithT4DNA ligase for 1 h at room temperature. A small aliquot of the
reaction was transformed into DH10B, and transformants were selected
on appropriate antibiotic plates. The success of the site-directed muta-
tion was confirmed by DNA sequencing of both strands of at least 2
independent clones.
Bacterial expression of proteins. SRF and SRF-S224A were cloned into
pGEX-4T-1 (GST tag vector) (BD Biosciences). BL21(DE3) strain of
Escherichia coli was transformed with the target constructs. Transfor-
mants were grown in LB medium until OD600 was 0.6 and induced
with 1mM IPTG at 16°C overnight. Bacteria were harvested the following
day, and GST-tagged target protein was purified using TALON affinity
cobalt column (Clontech) as per the manufacturer’s instructions. Puri-
fied proteinswere quantitated, snap-frozen in liquid nitrogen, and stored
as single-use aliquots at80°C.
In vitro kinase assay. The different mutants of GSK-3were expressed
and immunopurified from HEK293T cells as previously described (Cho
and Johnson, 2003). Briefly, HA-GSK-3-CA and HA-GSK-3-R96A
constructs were transfected intoHEK293T cells by AmaxaNucleofection
(Lonza). Immunoprecipitation assays were performed using anti-HA
antibody as described above with the followingmodification. In the final
step, beads were washed 3 times with 2 kinase buffer (40 mM Tris, pH
7.4, 20 mMMgCl2, and 2.5 mM CaCl2) and resuspended in the 2 kinase
buffer supplementedwith 20MATP.The beadswere incubatedwith the
same volume of bacterially purified GST-SRF, GST-SRFS224A, or GST
alone (1 g of protein used for SRF and S224A proteins and 0.373 g of
GST) along with 5 Ci of [- 32P]ATP. The samples were incubated at
37°C for 10 min, and the reaction was stopped by the addition of Laem-
mli buffer. The samples were then separated by SDS-PAGE gel, and the
radioactive signal was analyzed using a Phosphoimager.
In vivo kinase assay. HEK293T cells were cotransfected with HA-
tagged SRF or HA-SRFS224A along with Myc-GSK-3-WT, Myc-GSK-
3-KD, or Myc-GSK-3-CA. After 48 h, total lysate was prepared; SRF
was immunoprecipitated using anti-HA antibody and run on a 10%
SDS-PAGE gel. The Western blot was probed using a phospho-serine
antibody, anti-MPM2 (Invitrogen). The blot was then striped and
probed for total SRF.
Luciferase reporter gene assays. Luciferase assays were performed in
HEK293T. After transfection, cells were grown in serum-starved condi-
tion for 36 h; the medium was changed to that supplemented with 10%
FBS. Luciferase assay was performed using Dual Luciferase Assay kit
(Promega) 6 h after serum induction. Transfection efficiency was nor-
malized using a second reporter gene, Renilla luciferase, and compared
with unstimulated controls.
Statistical analyses. Statistical differences were determined with one-way
ANOVA followed by Tukey’s post hoc test or with two-tailed Student’s t test
using GraphPad Prism software. Error bars in figures are SEM. “n” within
the bars denotes the number of cells counted for analysis.
Microarray analysis.Total RNAwas isolated from the forebrain of P0.5
Srf-f/f and Srf-NestinCKO mice (n  2) using PureLink RNA mini kit
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(Ambion). A total of 5g of total RNAwas submitted to theMultiplexed
Gene Analysis Core Facility, Washington University School of Medicine
(St. Louis, Missouri) for quality control, labeling, hybridization, scan-
ning, and software services. Affymetrix Mouse Gene 1.0 ST was used for
the microarray, and data mining was performed using Partek Genomics
Suite software. Principal component analysis was performed to assess the
quality of the data. Genes that showed a fold change of at least 1.5 and a
present call in all 2 chips were considered. In addition, a two-tailed t test
with p  0.05 was applied. From the list of downregulated genes, only
those that were either part of, or predicted to interact with, the cytoskel-
etonwere used for further analysis. Figure 7 shows genes that were down-
regulated in Srf-NestinCKOmutant brains compared with control. After
validation using qRT-PCR, these genes were then screened for their abil-
ity to promote axon growth in SRF-deficient hippocampal neurons.
Image acquisition. Fluorescent and bright-field images were acquired
usingNikon 80i andNikon 90imicroscopes (Nikon Instruments), Roper
H2 cooled CCD camera (Photometrics), and Optigrid Structured Illu-
mination Confocal with a Prior (Rockland) motorized translation stage.
Pseudo-colored images were acquired in MetaMorph (Molecular De-
vices), filtered, and levels weremodified in ImageJ (National Institutes of
Health, Bethesda, Maryland) and Photoshop (Adobe) for clarity.
Results
GSK-3 phosphorylates SRF on a highly conserved
serine reside
SRF has been shown to regulate axonal growth in cultured hip-
pocampal andDRGneurons (Kno¨ll et al., 2006;Wickramasinghe
et al., 2008). Our recent findings using conditional SRF mutant
mice revealed that SRF is cell-autonomously required for growth
of several major axonal tracts, including corticostriatal and ento-
rhinal–hippocampal axonal projections in vivo (Lu and Ra-
manan, 2011). To understand the molecular mechanisms by
which SRF regulates axonal growth, we first sought to determine
howSRF activity is regulated in neurons. Transcription factors, in
general, are regulated by at least two mechanisms: post-
translational modifications and association with specific cofac-
tors. SRF has been shown to be phosphorylated upon synthesis,
but the regulation of its activity in neurons by phosphorylation
has not been reported (Misra et al., 1991; Rivera et al., 1993). We
took an in silico approach to identify phosphorylation sites on
SRF using Scansite (Obenauer et al., 2003). Among several resi-
dues identified as potential recognition motifs of different ki-
nases, serine 224 (ser228 in human SRF) was predicted to be the
single target site for GSK-3. This serine residue lies within pre-
viously described GSK-3 consensus sequence, S/T-X-X-X-S/T, in
which the first Ser or Thr is the phosphorylated residue (Doble
andWoodgett, 2003) (Fig. 1A). Ser224 is highly conserved across
species, and structural analyses suggested that this residue should
be distant from target DNA binding and accessible for modifica-
tion (Fig. 1A,B) (Pellegrini et al., 1995). Interestingly, GSK-3-
inhibited wild-type and SRF-deficient neurons exhibit similar
morphologies, including highly attenuated axon growth, suggest-
ing a possible functional link between SRF and GSK-3 (Goold et
al., 1999; Owen and Gordon-Weeks, 2003; Kim et al., 2006; Stern
et al., 2009; Hur et al., 2011).
Based on this prediction, we first examined whether SRF and
GSK-3 physically interact in the brain. Using pull-down assays
from wild-type brain lysates, we found that SRF and GSK-3 were
able to coimmunoprecipitate with each other (Fig. 1C). This was
further confirmed using Srf-NestinCKO and control brain ly-
sates, in which GSK-3 coimmunoprecipitated with SRF from
control lysate alone but not from Srf-NestinCKO lysate (Fig. 1C).
Together, these experiments suggest that GSK-3 either directly
interacts with SRF or associates with the SRF transcriptional
complex.
To address the functional relevance of the predicted phos-
phorylation and the coimmunoprecipitation results, we tested
whether GSK-3 directly phosphorylates SRF on ser224 residue
using in vitro kinase assay. Bacterially expressed and purified
GST, GST-SRFWT, or GST-SRFS224A was transiently incubated
withGSK-3-CA (constitutively active) orGSK-3-R96A (active
on unprimed substrates alone) or commercial GSK-3 kinase in
the presence of radioisotopic [-32P]ATP (Cho and Johnson,
2003). SRFS224A was generated by mutating serine 224 to alanine
by site-directed mutagenesis. We found that SRFWT was effi-
ciently phosphorylated by all three GSK-3 kinases (Fig. 1D). In
contrast, GST alone and SRFS224A mutant exhibited no phos-
phorylation signal in the presence of these GSK-3 kinases, sug-
gesting that the phosphorylation occurs specifically on ser224
(Fig. 1D). GSK-3 has been shown to phosphorylate two classes of
substrates, primed and unprimed, depending on the requirement
of a priming phosphorylation on a discrete residue c-terminal to
the target site (Frame et al., 2001; Doble and Woodgett, 2003).
The unprimed status of a substrate can be determined using the
GSK-3-R96A mutant, which can bind to and phosphorylate
only unprimed substrates (Frame et al., 2001; Kim et al., 2006;
Twomey and McCarthy, 2006). The phosphorylation of bacteri-
ally generated SRFWT, which should lack any priming phosphor-
ylation, by GSK-3-R96A suggests that SRF is an unprimed
substrate for GSK-3.
We next asked whether GSK-3 can also phosphorylate SRF in
vivo. This was studied using in vivo phosphorylation assays, in
which HEK293T cells were cotransfected with HA-SRFWT or
HA-SRFS224A alongwithGSK-3-WT,GSK-3-CA, or GSK-3-
KD. GSK-3-KD is a catalytically inactive mutant that functions
as a dominant-negative kinase and inhibits both GSK-3 and
GSK-3 (He et al., 1995; Kim et al., 2006; Kang et al., 2008). The
HA-SRFs were immunoprecipitated with anti-HA antibody and
phosphorylation was studied using a phospho-serine (pSer)-
specific antibody, anti-MPM2. We observed that SRFWT ex-
pressed alone exhibited a basal level of serine phosphorylation
and this is likely the result of phosphorylation on ser224 by en-
dogenous GSK-3 or on serine residues by other kinases (Fig. 1E)
(Misra et al., 1991; Rivera et al., 1993). Expression of GSK-3-CA
or GSK-3-WT increased pSer levels, whereas GSK-3-KD ex-
pression attenuated pSer signal (Fig. 1E,F). Interestingly, the
pSer signal on SRFWT in the presence of GSK-3-KD expression
was lower than that seen when SRFWT alone was expressed, con-
firming the hypothesis that endogenous GSK-3 contributes to
basal serine phosphorylation on SRF (Fig. 1F, left; compare
SRFWT  Myc vs SRFWT  GSK-3-KD). In contrast, SRFS224A
point mutant exhibited neither any increase in phosphoryla-
tion in the presence of GSK-3-CA or GSK-3-WT nor any
attenuation of pSer phosphorylation when coexpressed with
GSK-3-KD (Fig. 1E,F ).
Given that SRF is efficiently phosphorylated by GSK-3 both in
vitro and in 293T cells, we asked whether similar GSK-3-
mediated phosphorylation of SRF also occurs in neurons. We
inhibited GSK-3 kinases using the specific inhibitor, 6-
bromoindirubin-3-acetoxamine (6-BIO) (500 nM) and then
probed for SRF phosphorylation with anti-pSer antibody. 6-BIO is
a cell-permeable small-molecule inhibitor that is highly selective for
GSK-3butnot forother kinases, including cyclin-dependent kinases
(Meijer et al., 2003; Kim et al., 2006). We found that SRF was ro-
bustly phosphorylated in cultured hippocampal neurons, and this
phosphorylation was significantly attenuated in the presence of
6-BIO (Fig. 1G,H). Together, these experiments demonstrate that
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Figure 1. SRF interactswith and is phosphorylated by GSK-3 on ser224.A, Protein alignment shows that ser224 inmouse SRF (ser228 in human) is highly conserved among different species. The
boxed region represents the suggested GSK-3 consensus sequence, S/T-x-x-x-S/T.B, Analysis of the solved x-ray crystal structure of the N-terminus 1–223 amino acids of human SRF bound to DNA
shows that the aspartate residue at 223 is far away from the DNA binding region of SRF. Therefore, the target serine 228 (human), located five amino acids further c terminus, is unlikely to interfere
with DNA binding. C, SRF and GSK-3 interact in the brain. SRF was immunoprecipitated from whole-brain lysate of P0.5 wild-type mice and immunoblotted for GSK-3 and SRF (top). GSK-3 and
GSK-3were efficiently pulled down onlywith the SRF antibody and notwith anti-IgG control antibody. Likewise, GSK-3was able to pull down SRF only fromwild-type but not from Srf-NestinCKO
brain lysate (bottom). Pull down using IgG alone served as control.D, SRF is efficiently phosphorylated by GSK-3 in vitro. Kinase assays ware performed using bacterially generated GST, GST-SRF,
or GST-SRF S224A alongwith either GSK-3-CA, GSK-3-R96Amutant kinases or commercial recombinant wild-type GSK-3 in the presence of [- 32P]ATP. GST-SRF alone was phosphorylated by
GSK-3-CA, GSK-3-R96A, and wild-type GSK-3. In contrast, SRF S224A mutant and GST alone showed no signal suggesting that there are no other GSK-3 sites on SRF. E, SRF is also
phosphorylated by GSK-3 in vivo. HEK293T cells were transfected with HA-tagged SRFWT or HA-SRF S224A along with empty Myc vector or with each of the different Myc-tagged GSK-3 kinases.
SRF was pulled down with anti-HA antibody and immunoblotted using anti-phosphoserine (anti-MPM2) and anti-SRF antibodies. The level of phosphorylation of HA-SRFWT increased in the
presence of active GSK-3 kinases (WT and CA), whereas phosphorylation is attenuated in the presence of GSK-3-KD mutant kinase. SRF S224A mutant did not exhibit any changes in phosphor-
ylation levels.F, Densitometry analysis of results fromE shows changes inphosphorylation levels relative to that for SRFWTor SRF S224Aprotein levels. Error bars indicate SEM.***p0.001 (one-way
ANOVA, Tukey post-test analysis). n.s., Not significant. G, SRF is phosphorylated by GSK-3 in neurons. Hippocampal neurons from neonatal pups were grown (Figure legend continues.)
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SRF is anovel targetofGSK-3and isphosphorylated inanunprimed
manner on ser224 both in vitro and in cells.
Because GSK-3 phosphorylates SRF, we therefore examined
whether SRF phosphorylation is regulated in the brain during
development. SRF was immunoprecipitated from whole-brain
lysates at E13.5, E15.5, E18.5, P1, and P21, and status of serine
phosphorylation was probed using anti-pSer antibody (Fig. 1I).
SRF expression increased during development and remained higher
postnatally (Fig. 1I). In contrast, SRF phosphorylation levels in-
creased and peaked between E15.5 and E18.5. We then assessed for
GSK-3 activation by probing for GSK-3-Ser9 phosphorylation, a
measure of its inactivation (Cohen and Frame, 2001; Doble and
Woodgett, 2003). We observed that GSK-3-Ser9 phosphorylation
decreased betweenE15.5 andE18.5, suggesting thatGSK-3 activity
increases during this time, similar to that observed for SRF-Ser224
phosphorylation (Fig. 1I,J). This increase in SRF phosphorylation
appears to coincide with active axonal growth that occurs after neu-
rogenesis and is likely mediated by GSK-3.
Serine 224 phosphorylation by GSK-3 is critical for
SRF function
To assess whether ser224 phosphorylation is important for SRF
function, we asked whether SRFS224A mutant can rescue axonal
growth deficits of Srf-NestinCKO neurons. Reintroduction of
SRFWT into Srf-deficient neurons rescued axonal growth. In con-
trast, SRFS224A mutant was unable to rescue axonal growth in
Srf-NestinCKO neurons (Fig. 2A,B). Interestingly, SRFS224A
acted as a dominant-negative mutant when expressed in wild-
type neurons and attenuated axonal growth (Fig. 2C,D). We
compared this inhibitory effect of SRFS224A mutant on axonal
growth with two other dominant-negative SRF mutants, SRF-I
and SRF-En. SRF-I contains the N terminus homodimerization
and DNA binding domains alone but lacks the C terminus trans-
activation domain. SRF-I has been previously shown to be very
efficient in blocking activation of SRF-promoters in cultured cells
and is thought to function by either saturating SRF binding sites
on promoters or by sequestering endogenous SRF by forming
nonactive heterodimers (Kemp andMetcalfe, 2000). SRF-En is a
chimeric protein generated by fusing SRF-I with the repressor
domain (amino acids 2–298) of the engrailed gene fromDrosoph-
ila (Jaynes and O’Farrell, 1991). Engrailed is a homeodomain
protein and is a potent repressor of transcription. This repressor
domain, when fused to other transcription factors, has been
shown to function as dominant-negative regulators of transcrip-
tion (Badiani et al., 1994; Vickers and Sharrocks, 2002; Vickers et
al., 2004). Expression of SRF-I and SRF-En in wild-type neurons
also resulted in attenuated axonal growth similar to that of
SRFS224A mutant (Fig. 2C,D).
We next determined the effect of GSK-3 inhibition and SRF-
S228A mutation on SRF-dependent transcription. For this,
HEK293T cells were transfected with SRE-luciferase reporter
constructs and treatedwith either 6-BIO to inhibit GSK-3 activity
or cotransfected with SRFWT, SRFS224A, SRF-VP16, SRF-I, and
SRF-En (Fig. 2E). SRF-VP16 is a constitutively active chimeric
protein, which is generated by fusing 260 amino acids of SRF N
terminuswith the strong transactivation domain of VP16 protein
from herpes simplex virus. SRF-VP16 transcriptional activity has
not been shown to depend on cofactor requirement or post-
translational modifications. Expression of SRF-VP16 results in
increased reporter activation, even in the absence of any inducing
stimulus (Fig. 2E). Inhibition of GSK-3 activity blocked serum-
induced SRF-dependent transcription (Fig. 2E). Unlike SRFWT
but similar to SRF-I and SRF-En, SRFS224A mutant was also
incapable of activating SRF-dependent transcription (Fig. 2E).
Together, these experiments suggest that GSK-3 activity and SRF-
Ser224 phosphorylation is critical for SRF function in neurons.
Phosphorylation of SRF by GSK-3 is necessary for MKL
cofactor binding
Given that Ser224 phosphorylation byGSK-3 is necessary for SRF
function, a critical question is how Ser224 phosphorylation con-
tributes to SRF-dependent transcription. One of the widely de-
scribed regulatory mechanisms for SRF-dependent transcription
is its association with specific cofactors (Sharrocks, 2001; Cen et
al., 2004). We therefore asked whether SRFS224A mutant can in-
teract with TCF-family member ELK1 and myocardin-family
members MKL1 and MKL2 using coimmunoprecipitation as-
says. HEK293T cells were cotransfected with HA-tagged SRFWT
or SRFS224A along with Flag-MKL1 or Myc-MKL2. SRF was im-
munoprecipitated with anti-HA antibody and immunoblotted
for Flag or Myc epitopes. S224Amutation specifically attenuated
SRFbinding toMKL1andMKL2 (Fig. 3A,B). ToprobeELK1 inter-
action, the ability of SRFWT and SRFS224A mutant to immunopre-
cipitate endogenous activated phospho-ELK1 (pELK1) was
analyzed. In contrast to MKL1 and MKL2, the interaction of
SRFS224AmutantwithpELK1wasunaffected (Fig. 3C,D), suggesting
that phosphorylationof ser224byGSK-3 is necessary for the recruit-
ment ofMKLs, but not TCF-family cofactors, onto SRF.
Previous studies have shown that the MKL-family cofactors
are required for axonal growth (Kno¨ll et al., 2006; Wickramas-
inghe et al., 2008; Mokalled et al., 2010; O’Sullivan et al., 2010).
Consistent with these studies, we found that expression of a
dominant-negativeMKL2 (DN-MKL2), which inhibits the activ-
ities of both MKL1 and MKL2, can block axonal growth in hip-
pocampal neurons (Selvaraj and Prywes, 2003) (Fig. 3E,F). Thus
far, the requirement for TCF-family cofactors in regulating axon
growth has not been studied. Elk1-nullmice are viable and do not
exhibit any structural abnormalities in the brain, and this is at-
tributed to compensation by family members, Sap1 and Sap2
(Cesari et al., 2004). To address the requirement of TCF-family
cofactors for axon growth, we expressed ELK1-Engrailed (ELK1-
En), a chimeric protein generated by fusing ELK1 coding region
with the strong transcriptional repressor domain of theDrosoph-
ila gene, Engrailed. ELK1-En has been shown to efficiently inhibit
the activities of all three members of the TCF family (Vickers and
Sharrocks, 2002; Vickers et al., 2004). Expression of ELK1-En in
hippocampal neurons did not affect axon outgrowth (Fig. 3G,H).
Together, these data suggest that phosphorylation of ser224 by
4
(Figure legend continued.) for 3 d in the presence of either DMSO (vehicle) or 500 nM 6-BIO to
inhibit GSK-3. Endogenous SRFwas immunoprecipitatedwith anti-SRF antibody and immuno-
blottedwith anti-phosphoserine antibody. The level of serine phosphorylation decreased in the
presence of 6-BIO comparedwith DMSO-treated control.H, Densitometric analysis of phospho-
SRF to total SRF levels from G shows significant decrease in SRF serine phosphorylation in the
presence of 6-BIO relative to DMSO control. Error bars indicate SEM. I, Changes in SRF andGSK-3
phosphorylation during brain development. SRF was immunoprecipitated from whole-brain
lysates of wild-type embryos and pups at the indicated stages and immunoblotted with pSer
antibody. GSK-3 activity was measured by immunoblotting for GSK-3-Ser9 phosphoryla-
tion. SRF expression increased during development, whereas the level of pSer phosphorylation
peakede15.5-e18.5.GSK-3-Ser9phosphorylationdecreasedbetweene15.5ande18.5andpost-
natally, suggestingGSK-3activationduring this timeperiod. J, Densitometric analysis ofpSer levels
and GSK-3-pSer9 from I shows increase in pSer phosphorylation of SRF and GSK-3e15.5 to
e18.5.Errorbars indicateSEM.***p0.001(one-wayANOVA,Tukeypost-testanalysis).**p0.01
(one-wayANOVA, Tukey post-test analysis).
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GSK-3 and subsequent binding of MKLs and not TCF-family
members contribute to SRF-dependent axon growth.
SRF can rescue axon outgrowth deficits caused by
GSK-3 inhibition
Based on the above findings, we hypothesized that SRF likely func-
tions downstream of GSK-3 signaling and that activation of SRF-
dependent gene expression should be able to promote axonal
growth when GSK-3 kinases are inhibited. To test this, SRF-
dependent gene expression was activated using constitutively active
SRF-VP16,whereasGSK-3 kinaseswere inhibited byLiCl (2mM)or
6-BIO (500 nM) (Meijer et al., 2003; Kim et al., 2006). 6-BIO at 300
nM concentrations was found to be efficient in blocking GSK-3 ac-
tivity and axonoutgrowth inDRGneurons (Kimet al., 2006;Alabed
et al., 2010). However, we found that 500 nM of 6-BIO was more
efficient inblockingaxonal growth inhippocampalneuronswithout
affectingneuronal survival (datanot shown).Consistentwith earlier
reports, culturing hippocampal neurons in the presence of LiCl or
6-BIOseverely attenuated axonal growth (Kimet al., 2006;Alabed et
al., 2010) (Fig. 4A,B; and data not shown). SRF-VP16 expression in
neurons grown in the presence of 6-BIO or LiCl was able to signifi-
cantly promote axon growth compared with IRES-EGFP control
Figure 2. Serine 224 is required for SRF function. A, SRF S224A mutant cannot rescue axonal growth deficits of SRF-deficient neurons. P0.5 hippocampal neurons from Srf-NestinCKO mice were
transfected with IRES-EGFP empty vector, HA-SRFWT, or HA-SRF S224A. Cells were fixed and immunostained for GFP or HA (green) to visualize transfected cells and anti-Tuj1 (red) at 4 DIV. Axonal
growth deficits exhibited by SRF-deficient neurons were rescued by SRFWT alone and not by empty vector or SRF S224A (arrows). Arrowhead indicates an untransfected cell. Scale bar, 50m. B,
Quantitation of axon length from A. n 4 mice; “n” in the bars indicates the number of cells measured for statistics. Error bars indicate SEM. ***p 0.001 (one-way ANOVA, Tukey post-test
analysis). n.s., Not significant. C, SRF S224A functions as a dominantmutantwhen expressed inwild-type hippocampal neurons. Cells were transfectedwith HA-SRFWT or HA-SRF S224A and grown for
4 DIV. Cells were fixed and immunostained with anti-HA (green) and anti-Tau (red) antibodies. HA-SRF S224A expression attenuated axonal growth (arrows). Scale bar, 50m. D, Data quantified
from C. Error bars indicate SEM. ***p 0.001 (one-way ANOVA, Tukey post-test analysis). E, Inhibiting GSK-3 activity or mutating serine 224 to alanine abolishes SRF transcriptional activity.
HEK293T cells were transfected with 5-SRE luciferase and Renilla luciferase (for transfection efficiency) and treated with either 6-BIO or cotransfected with control vector, SRFWT, SRF-S224A, or
SRF-VP16. 6-BIO treatment blocked serum-induced SRF-transcriptional activity.Whereas vector and SRFWT transfected cells showed normal activation of an SRE reporter, the SRF S224Amutant was
severely compromised in activating transcription. Expression of constitutively active SRF-VP16 served as the control. Error bars indicate mean	 SEM.
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Figure 3. Serine 224 phosphorylation is required for SRF interactionwithMKL-family cofactors andnotwith TCF-family cofactor ELK1.A, HEK293T cellswere cotransfectedwithHA-SRFWT or HA-SRF S224A
along with Flag-MKL1 or Myc-MKL2. Immunoprecipitation with anti-HA antibody pulled down significantly less MKL1 (left) and MKL2 (right) from HA-SRF224A-transfected cells. The expression levels of
Flag-MKL1,Myc-MKL2,andHA-SRFwere thesameinbothgroupsof transfectedcells.-Tubulin levels inequalamountsof lysatesused for IPservedas loadingcontrol.B,Densitometricanalysisof immunoblot
inA. Error bars indicate SEM.C, Serine 224 to alaninemutation does not affect SRF interactionwith the TCF-familymember ELK1. HEK293T cellswere transfectedwithHA-SRFWT orHA-SRF S224A. Immunopre-
cipitationwithanti-HAantibodyandimmunoblottingforendogenousactivatedELK1usinganti-phosphoELK1(pELK1)antibodyshowedthatasimilaramountofpELK1wasimmunoprecipitatedwithHA-SRFWT
andHA-SRF S224A. Levelsof SRF in the immunoprecipitateswere similar and-tubulin levels inequal amountsof lysatesused for IP servedas loadingcontrol.D, Densitometric analysis of immunoblot inC. Error
bars indicateSEM.n.s.,Not significant.E,MKL1andMKL2are required foraxongrowth.Neonatalwild-typehippocampalneuronswere transfectedwith IRES-EGFPvectororDN-MKL2-IRES-EGFP. Expressionof
DN-MKL2 blocked axonal growth (arrow) as visualizedwith anti-Tau (red) and anti-GFP (green). Scale bar, 50m. F, Quantitation ofD. Error bars indicate SEM; n 3mice. ***p 0.001 (two-tailed t test
analysis).G, Inhibition of TCF-family cofactors does not affect axonal growth. Hippocampal neurons fromwild-type neonatal pupswere transfectedwith dominant-negative Elk1-En (bottom) or empty vector
(top).CellswerestainedforTuj1(red)andFlagepitope(green)at4DIV.ExpressionofElk1-En,which inhibitsall threemembersoftheTCFfamily,doesnotaffectaxonalgrowth.Scalebar,50m.H,Quantitation
of axon length inG. Error bars indicate SEM;n 3mice. p 0.8087 (two-tailed t test analysis).
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vector (Fig. 4A,B; and data not shown). Expression of SRF-VP16
alone inneurons didnot produce any additional growth-promoting
effects under normal conditions (Fig. 4D). We next asked whether
this rescue specifically requires SRF or whether other transcription
factors can promote axonal growth under conditions of GSK-3 in-
hibition. Previous studies using knock-out mice have shown that
CREB is required for axonal growth in peripheral neurons (Lonze et
al., 2002; Gao et al., 2004). Expression of constitutively active CREB
(VP16-CREB) was unable to rescue the growth deficits resulting
from GSK-3 inhibition, indicating that CREB-dependent gene ex-
pressionmight be insufficient to rescue axonal growth whenGSK-3
is inhibited (Fig. 4A,B). In addition to pharmacological inhibition,
we also expressed GSK-3-KD, which acts as a dominant-negative
mutant and has been shown to attenuate axon growth in cultured
hippocampal neurons (Fig. 4C) (Kim et al., 2006). Similar to that
seen for 6-BIO-mediated inhibition, expression of GSK-3-KD in
hippocampal attenuated axonal growth, and this was rescued by
SRF-VP16 expression (Fig. 4C,D). Together, these findings suggest
that SRF functions downstream of GSK-3 and that activation of
SRF-dependent expression can promote axon growth when GSK-3
activity is inhibited.
SRF is required during Stage 1 neurite growth and
axon extension
Given the importance of SRF for axon growth in vitro and in vivo,
it is critical to know when SRF-dependent transcription is re-
Figure 4. SRF can rescue axonal growth deficits caused by GSK-3 inhibition. A, P0.5 hippocampal neurons from wild-type mice were transfected with either empty IRES-EGFP vector or
constitutively active SRF (SRF-VP16-IRES-EGFP) or constitutively active CREB (VP16-CREB) andgrown in thepresenceof theGSK-3-specific inhibitor 6-BIO (500nM) orDMSO (vehicle). Cellswere fixed
and immunostained using anti-Tau (red) and GFP or VP16 (green) at 4 DIV. GSK-3 inhibition by 6-BIO results in attenuation of axonal growth (top, arrowhead), and this was rescued by expression
of SRF-VP16 (middle). Expression of a constitutively active CREB (VP16-CREB) was unable to promote axonal growth under similar growth conditions (bottom). Arrows indicate dead cells/debris.
Scale bar, 50m.B, Quantitation ofA. Error bars indicate SEM. **p 0.01 (two-tailed t test analysis). ***p 0.001 (two-tailed t test analysis). n.s., Not significant. C, Hippocampal neuronswere
cotransfected with GSK-3 constructs and SRF-VP16 as indicated above and grown for 4 d. Expression of GSK-3-KD attenuated axon growth (middle). This attenuation was rescued by SRF-VP16
expression (bottom). Expression of GSK-3-WT alone had no influence on axon outgrowth. Arrows indicate dead cells/debris. Scale bar, 50m.D, Axon length quantified from C. Error bars indicate
SEM. ***p 0.0001 (one-way ANOVA, Tukey post-test analysis).
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quired during axon development. In cultures, hippocampal and
neocortical neurons follow a stereotypic pattern of growth (Craig
and Banker, 1994; de Lima et al., 1997). When dissociated and
cultured, neurons form extensive filopodial and lamellipodial pro-
trusions at the periphery (Stage 1) followed by extension of several
neurites (Stage 2). Subsequently one of these neurites elongates rap-
idly inanasymmetricmanner tobecome theaxon(Stage3) followed
by dendritic specialization and growth (Stage 4) (Craig and Banker,
1994; de Lima et al., 1997). Hippocampal neurons cultured from
neonatal Srf-NestinCKO mice and control littermates were fixed
and stained for Tuj1 and MAP2 at the indicated time points and
axonal length (Tuj1/MAP2 process) was determined at each
time point (Fig. 5A). We found that neurons cultured from both
control and knock-out mice extended a single Tuj1/MAP2 pro-
cess, which alone was positive for the axonal marker, Tau (data not
shown). In contrast, neurons from Srf-NestinCKO mice displayed
no or very few processes, which exhibited almost no growth in the
first 2 d (Fig. 5A,B). Subsequently, the average length of the axon in
SRF-deficient neurons increased slightly but still was significantly
lower than that of control neurons (Fig. 5A,B). At 5 d, Srf-
NestinCKOneurons exhibited significantly attenuated axon growth
along with an enlarged growth cone compared with Srf-f/f neurons
(Fig. 5A,B).
Analysis of axonal growth strongly suggested that the earliest
deficits exhibited by Srf-NestinCKO neurons are in Stage 1
growth. During Stage 1, cell symmetry is breached by filopodial
protrusions from cell soma, which is a necessary first step in the
generation of neurites (Craig andBanker, 1994;Dent et al., 2007).
To study Stage 1 growth in detail, hippocampal neurons from
Srf-NestinCKO and control littermates were fixed and stained
with phalloidin to visualize F-actin-rich filopodial protrusions at
12, 24, and 48 h after plating. We found that SRF-deficient neu-
rons had very few or no filopodia at 12 and 24 h compared with
numerous filopodial protrusions exhibited by control neurons
(Fig. 5C,D; and data not shown). At 48 h, control neurons had
extended neurites withmany filopodia at the tips. In contrast, the
Figure 5. SRF-deficient neurons are deficient in Stage 1 neurite growth and exhibit attenuated axonal growth in vitro. A, Hippocampal neurons from Srf-NestinCKO mice exhibit delayed and
attenuated axonal growth as visualized by immunostaining with Tuj1 (red) and MAP2 (green). SRF-deficient neurons produced fewer neurites at 12 h (arrows, left second row panels) and, at 5 d,
had shorter axons and enlarged growth cone (right bottom, arrow). Control neurons extended longer axon (right middle, arrow) andmultiple dendrites. Arrowheads indicate dead cells. Scale bar,
50m. B, Axonal growth in Awas studied by measuring the length of the Tuj1/MAP2 process at the indicated time points. Error bars indicate SEM. C, Srf-NestinCKO neurons are deficient in
filopodia formation. Rhodamine-conjugated phalloidin reveals several filopodia (12 h, arrows) and distinct neurites (48 h) in control neurons. In contrast, mutant neurons had fewer or no filopodia
(arrow) and an enlarged cell body. Scale bar, 12.5m. D, Histograms of the total filopodia counted from C. p 0.0001 (two-tailed t test analysis). E, Immunostaining with axon-specific PanNaV
(green) and Tuj1 (red) antibodies shows normal polarization of Srf-NestinCKO neurons as observed for Srf-f/f neurons (n 32). Scale bar, 25m.
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SRF-deficient neurons exhibited few or no distinguishable neu-
rites or filopodia (Fig. 5A–D). SRF-deficient neurons also exhib-
ited an enlarged growth cone as previously reported (Kno¨ll et al.,
2006) and an enlarged cell soma. It has been reported that SRF-
deficient neurons lack filopodia in growth cones of extending
axons (Stern et al., 2009). Because filopodia formation is a critical
step in neuronal growth, it is reasonable to speculate that the
severe Stage 1 growth deficits observed in Srf-NestinCKO neu-
rons are likely the result of inability ofmutant neurons to form or
stabilize filopodia. Together, these findings demonstrate that
SRF-dependent transcription plays a critical role in filopodia for-
mation during early stages of axon growth.
Although SRF-deficient neurons exhibited highly attenuated
axonal growth, these neurons extended a single Tau-positive
axon indicating that cell polarity is not affected. To further con-
firm this, we immunostained hippocampal neurons from Srf-
NestinCKO mice and control littermates with a pan sodium
channel antibody (Pan-NaV) directed against the  subU (intra-
cellular III–IV loop) of all vertebrate channels. This Pan-NaV
antibody labels only the proximal part of the axon (Garrido et al.,
2003; Kress et al., 2010). We found that SRF-deficient neurons
extended a single Pan-NaV-positive neurite suggesting that neu-
ronal polarity is not impaired in the absence of SRF (Fig. 5E).
Actin-binding protein, vinculin, can rescue growth defects of
SRF-deficient neurons
We next sought to identify the downstream target genes of SRF
that are important for axon growth. We performed a microarray
analysis to identify genes differentially expressed in the forebrain
of neonatal Srf-NestinCKOmutant mice and control littermates
(Fig. 6A). Because SRF-deficient neurons exhibited deficits in
filopodia formation, we reasoned that proteins that bind actin
and stabilize the actin cytoskeleton might be good candidates to
rescue axon growth. We therefore considered only those down-
regulated genes that are either part of, or interact with, the cyto-
skeleton and validated their expression using qRT-PCR (Fig. 6B).
Wenext askedwhich of these genes could rescue axonal growth in
SRF-deficient neurons. Expression of cortexin, nexillin, and
Rusc1 did not promote axonal growth in Srf-NestinCKOneurons
(data not shown).However, expression ofVCL andmicrotubule-
associated protein 1B (MAP1B) was able to promote axon out-
growth in SRF-deficient neurons to varying extents. VCL is a
previously identified SRF target gene, and earlier studies using
chromatin immunoprecipitation and gene expression assays
have shown that Vcl is a direct target of SRF and MKL1
(Moiseyeva et al., 1993; Schratt et al., 2002; Miralles et al., 2003;
Cooper et al., 2007). VCL is an actin-binding protein and a com-
ponent of cell–matrix junctions. In cultured CNS neurons, VCL
is localized in cell soma, at the ends of neurites and along with
focal adhesion kinase (Stevens et al., 1996; Contestabile et al.,
2003). Studies fromcultured cells have shown thatVCL functions
as a bridge between actin cytoskeleton and extracellular matrix
(Ziegler et al., 2006; Humphries et al., 2007). Despite these find-
ings, the functions of VCL in the nervous system remain poorly
understood because of early embryonic lethality of Vcl-nullmice
due to cardiac and neural tube defects (Xu et al., 1998).MAP1B is
a member of a large class of microtubule-associated proteins that
function in stabilizing the microtubule (Dehmelt and Halpain,
2004). It is important for axon growth, and its function is regu-
lated by phosphorylation by GSK-3 (Dehmelt and Halpain,
2004; Gonzalez-Billault et al., 2004).
Expression of both Vcl andMap1b was severely attenuated in
the brains of Srf-NestinCKO mice (Figs. 6, 7A, and 8A). We
found that expression ofMap1b partially rescued axonal growth
but failed to rescue the enlarged growth cone and abnormal cell
soma phenotypes observed in SRF-deficient neurons when cells
were grown on poly-D-lysine and laminin (Fig. 7B,C). In con-
trast, Vcl expression was able to rescue axonal growth as well as
enlarged growth cone and cell soma phenotypes exhibited by
Srf-NestinCKO neurons when neurons were grown on poly-D-
lysine and laminin (Fig. 8B,C). Because VCL is a critical player in
coupling integrin signaling to the dynamic actin cytoskeleton, we
tested the ability of VCL to rescue axonal growth deficits of SRF-
deficient neurons grown in the absence of laminin. We found
that Vcl expression only partially rescued axonal length of SRF-
deficient neurons grown on poly-D-lysine alone in the absence of
laminin (Fig. 8D,E). This suggested that efficient rescue of
growth deficits exhibited by SRF-deficient neurons by VCL likely
involves laminin and integrin signaling. Expression of VCL in
wild-type neurons did not have any additional growth-
promoting effects (Fig. 8C,E). Together, these data suggest that
both VCL and MAP1B are capable of rescuing axon growth in
SRF-deficient neurons, but VCL is more efficient and VCL alone
can rescue the enlarged growth cone and cell somamorphologies.
Figure 6. Putative SRF target genes identified from forebrain. A, Table represents Srf target
genes identified from forebrain of neonatal Srf-f/f and Srf-NestinCKO mice. The genes in bold
were further analyzed for their ability to rescue axonal growth deficits of Srf-NestinCKOmutant
neurons. B, mRNA expression of Srf target genes in A. Relative mRNA expression levels were
assessed by real-time qRT-PCR. The expression level in control sample was set to 1 (n 3
experiments).
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Phosphorylation of SRF by GSK-3 promotes SRF-MKL1
binding, and SRF and MKL1 regulate Vcl expression (Schratt et
al., 2002; Miralles et al., 2003). Based on these observations, we
asked whether VCL can also promote axon growth when GSK-3
is inhibited. We first assessed the status of Vcl expression under
conditions of GSK-3 inhibition and subsequent rescue by SRF-
VP16 (Fig. 9A). Hippocampal neurons treated with 6-BIO exhib-
ited significant reduction inVclmRNA expression as determined
by qRT-PCR, and expression of SRF-VP16 in the presence of
6-BIO resulted in increased Vcl mRNA (Fig. 9A). We next ex-
pressed VCL in wild-type hippocampal neurons grown in the
presence of 6-BIO and found that VCL expression significantly
increased axon length (Fig. 9B,C). Last, we asked whether VCL is
necessary for axon growth. Using shRNA specific for mouse Vcl,
we found that Vcl knockdown resulted in attenuated axonal
growth similar to that observed in SRF-deficient neurons (Fig.
9D,E; and data not shown). Coexpression of a chicken homolog
ofVcl, which is functionally similar to mouseVcl, rescued axonal
growth (Fig. 9D,E) (Grashoff et al., 2010). The chicken Vcl is
resistant to mouse shVcl, suggesting that axonal growth deficits
caused by shVcl are not the result of off-target effects. Together,
these observations demonstrate that SRF promotes axon out-
growth downstream of GSK-3 partly through regulation of
MAP1B and VCL expression.
Discussion
In this study,we report a novel phosphorylation of SRF,mediated
by GSK-3, that is required for SRF transcriptional activity and for
SRF-dependent axon growth. SRF is an
unprimed transcriptional substrate of
GSK-3, and GSK-3 inhibition results in
reduced SRF phosphorylation and SRF
activity, which attenuates axon growth.
Phosphorylation of SRF on serine 224 is
necessary for SRF to interact with its co-
factors MKL1 and MKL2. Moreover, SRF
is sufficient to promote axonal growth
in the absence of GSK-3 signaling in
cultured hippocampal neurons. Further-
more, SRF regulates axonal growth through
regulation of VCL and MAP1B expres-
sion. Finally, knockdown of VCL attenu-
ates axonal growth, andVCL can promote
axonal growth in the absence of SRF and
GSK-3 signaling. Together, our findings
suggest that SRF promotes axon growth
by likely activating gene expression down-
stream of GSK-3 signaling in hippocam-
pal neurons.
Given the importance of SRF for neu-
ral development, activity-dependent gene
expression, and synaptic plasticity, sur-
prisingly little is known about the post-
translational modifications that activate
SRF downstream of diverse cellular sig-
nals. Previous studies have shown that
SRF is phosphorylated on several serine
and threonine residues, but the impor-
tance of this phosphorylation for SRF
transcriptional activity remains unclear
(Misra et al., 1991; Rivera et al., 1993; Iyer
et al., 2006). In this study, we have identi-
fied a novel phosphorylation mechanism
by which SRF is activated in neurons and
how this contributes to SRF-dependent axon growth (Fig. 10).
SRF is directly phosphorylated by GSK-3 on ser224 that lies out-
side the MADS-domain required for DNA binding and SRF ho-
modimerization (Pellegrini et al., 1995). Furthermore, global
inhibition of GSK-3 activity in cultured neurons attenuated SRF
phosphorylation and SRF transcriptional activity (Figs. 1 and 9).
However, currently it remains unknown whether the decrease in
SRF phosphorylation is the result of GSK-3 inhibition in the
nucleus or axons and whether nucleus-specific GSK-3 inhibition
alone can block axon growth. A recent study revealed a novel
mechanism by which cytoplasmic SRF promoted axon regenera-
tion after peripheral nerve injury in a transcription-independent
manner through interactions with cofilin (Stern et al., 2013). It is
possible that pSer224-SRF might have a similar cytoplasmic role
during axon growth. However, this is unlikely because the
SRFS224A point mutant acted in a dominant-negative manner
and attenuated both transcription and axon growth. Future ex-
periments will address the effect of nucleus- and axon-specific
inhibition of GSK-3 on SRF phosphorylation and axon growth.
Previous studies have shown thatGSK-3 can shuttle between
cytoplasm and nucleus and that GSK-3 is present in the nucleus
where it interactswith transcription factors (Bijur and Jope, 2003;
Caspi et al., 2008; Bechard and Dalton, 2009). In the context of
GSK-3/SRF interaction, it remains unclear whether SRF is con-
stitutively phosphorylated by GSK-3 in the nucleus or whether
their interaction is triggered by growth-promoting signals and/or
actin-cytoskeletal changes. Future studies will address whether
Figure 7. MAP1B expression is attenuated in SRF-deficient neurons. A, Lack of expression of MAP1B in SRF-deficient neurons.
SemiqRT-PCR of total RNA isolated from brains of Srf-NestinCKO mice and Srf-f/f control littermates (n 3). RPS29 expression
served as the control. B, MAP1B expression partially promotes axon growth in SRF-null neurons. Hippocampal neurons from
neonatal Srf-NestinCKO mice were transfected with either control myc vector or myc-tagged MAP1B along with farnesylated GFP
(F-GFP)andgrownfor4donpoly-D-lysineand laminin.MAP1Bwasable topartially increaseaxonal length inSRF-deficientcells.However,
MAP1Bwas not efficient in rescuing the enlarged growth cone (arrows) and abnormal cell soma (arrowheads)morphologies observed in
SRF-deficient neurons. Expression of MAP1B did not increase axonal growth in WT neurons. Scale bar, 50 mm. C, Quantitation of axon
length andgrowth cone area fromB. ***p 0.001 (one-wayANOVAand Tukey post-test analysis). n.s., Not significant.
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Figure 8. Vinculin is sufficient to promote axonal growth in SRF-deficient neurons. A, Western blot of total brain lysate showing reduced Vcl expression in Srf-NestinCKO mice compared with
control littermates.B, P0.5 hippocampal neurons from Srf-NestinCKO and Srf-f/fmicewere cotransfectedwith empty vector (pMyc) or pMyc-VCL and cultured for 4 DIV on poly-D-lysine and laminin.
Cellswere fixedand immunostained for Tuj1 (red) andMyc (green). ExpressionofVclbutnot emptyvectorwasable topromoteaxongrowth. Scalebar, 25m.C, QuantitationofB. Error bars indicate
SEM. ***p 0.001 (one-way ANOVA, Tukey post-test analysis). n.s., Not significant. D, Vinculin only partially rescues axonal growth in SRF-deficient neurons in the absence of laminin. P0.5
hippocampal neurons from Srf-NestinCKO and Srf-f/f mice were cotransfected with empty vector (pMyc) or pMyc-VCL along with farnesylated-GFP (F-GFP) and cultured for 4 DIV on poly-D-lysine
alone without laminin. Cells were fixed and immunostained for GFP (green) to visualize neuronal morphology and Myc (red) for transfected cells. Expression of VCL, but not empty vector, could
partially rescue axonal growth in the absence of laminin, suggesting a role for laminin–integrin signaling downstream of VCL in promoting axon growth. Scale bar, 25m. E, Quantitation of axon
length in D. ***p 0.001 (one-way ANOVA, Tukey post-test analysis).
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extrinsic factors, such as neurotrophins and actin cytoskeletal
changes, result in SRF ser224 phosphorylation. These studies will
provide additional insights into how extracellular signals are con-
veyed to the nucleus for efficient axonal growth.
During development, we observed that ser224 phosphoryla-
tion on SRF increased between E15.5 and E18.5 and decreased
subsequently. In contrast, at E15.5, we found relatively higher
GSK-3-Ser9 phosphorylation, a measure of its inactivation.
Thus, it seems to appear that SRF-Ser224 phosphorylation does
not closely correlate temporally with GSK-3 activity in the
brain. A parsimonious explanation for this is that we measured
total GSK-3 activity in whole-brain lysates, and this might not
Figure 9. Vinculin can partially rescue axonal growth in the absence of GSK-3 signaling. A, Vcl mRNA expression is attenuated in neurons when GSK-3 is inhibited. Vcl mRNA expression was
assessed by real-time qRT-PCR from total RNA isolated from hippocampal neurons grown in the presence of DMSO (con), 500 nM 6-BIO or 6-BIOSRF-VP16 at 3 DIV. VclmRNA levels decreased in
the presence 6-BIO and expression of SRF-VP16 rescuedVcl levels. ***p 0.001 (one-way ANOVA, Tukey post-test analysis). n.s., Not significant.B, VCL expressionwas also able to promote axonal
growthwhen GSK-3 is blocked by 6-BIO.Wild-type hippocampal neuronswere transfectedwith either emptyMyc vector orMyc-VCL and cultured in the presence of DMSO (vehicle) or 500 nM 6-BIO
for 4 DIV on poly-D-lysine and laminin. Cells were fixed and immunostained forMyc (green) and Tuj1 (red). VCL expression alone promoted axonal growth (arrow). Scale bar, 25m. C, Quantitation
of B. Error bars indicate SEM. **p 0.005 (6-BIOMyc vs 6-BIOMyc-VCL) (two-tailed t test analysis). ***p 0.0002 (6-BIOMyc vs 6-BIOMyc-VCL) (two-tailed t test analysis). D, shRNA
knockdown of VCL expression in hippocampal neurons attenuates axonal growth.Wild-type hippocampal neurons were transfected with shRNA targetingmouse Vcl (Vcl-shRNA-CMV-mCherry) or
a control shRNA (shRNA-CMV-mCherry) alongwith YFP and grown for 4 d. Cells were fixed and stained for mCherry encoded fromwithin the shRNA vector and YFP. For rescue experiment, neurons
were transfected with Vcl-shRNA along with the chicken homolog, venus-chicken Vcl (Ch-Vcl). Ch-Vcl is resistant to mouse Vcl-shRNA, and its expression rescued axonal growth (arrow). Scale bar,
25m. E, Quantitation of D. Error bars indicate SEM. **p 0.01 (one-way ANOVA, Tukey post-test analysis). ***p 0.001 (one-way ANOVA, Tukey post-test analysis).
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accurately reflect the activity of nuclear
GSK-3. However, a previous study had
shown that GSK-3 activity increases
during brain development when assessed
for GSK-3 targets, such as c-Myc and
-catenin (Kim et al., 2009), and these
findings appear to be consistent with our ob-
servations for SRF ser224 phosphorylation.
The ser224 phosphorylation is specifi-
cally required for SRF to form a functional
transcriptional complex with the cofac-
torsMKL1 andMKL2 and not with ELK1.
Among these two groups of cofactors, the
MKLs alone have been shown to regulate
axonal and dendritic growth in hip-
pocampal, neocortical, and embryonic
DRG neurons (Shiota et al., 2006; Wick-
ramasinghe et al., 2008; Mokalled et al.,
2010; O’Sullivan et al., 2010). The role for
TCF-family members in neuronal devel-
opment remains unclear. We found that,
unlike dominant-negative MKL2, expres-
sion of a dominant-negative ELK1-En,
which inhibits all TCF-family members,
in cultured hippocampal neurons did not
affect axon growth (Fig. 3G,H). There-
fore, it appears that TCF-target genes are
unlikely to regulate axon growth in hip-
pocampal neurons. Based on these obser-
vations, we speculate that SRFS224A acts as
a dominant-negative mutant by forming heterodimers with en-
dogenous wild-type SRF, thereby preventing the formation of a
functional SRF-MKL complex. Currently, it is unclear whether
the ser224 phosphorylation is also required for other functions of
SRF, including activity-dependent immediate early gene expres-
sion and synaptic plasticity (Ramanan et al., 2005).
Previous studies have shown that pharmacological inhibition
of the MEK pathway or expression of dominant-negative
ELK1-En did not affect Vcl expression (Gineitis and Treisman,
2001; Vickers et al., 2004). Instead, expression of DN-MKL1,
which blocks both MKL1 and MKL2 or inhibition of actin po-
lymerization by latrunculin-B blocksVcl expression (Gineitis and
Treisman, 2001; Cen et al., 2003). Together, these findings imply
that Vcl expression is independent of Elk1/TCF-family members
and ERK/MEK pathway activation. Consistent with these find-
ings, we found that ELK1-En expression did not inhibit axon
outgrowth, whereas DN-MKL2 expression profoundly inhibits
growth likely by inhibiting genes, including Vcl.
Interestingly, hippocampal neurons lacking SRF or inhibited
forGSK-3 activities exhibit similar growth phenotypes in culture.
Both these groups of neurons exhibit a delay in Stage 1 growth
observed in the first 12–24 h (Fig. 5; and data not shown). How-
ever, SRF-deficient neurons were able to extend a single but sig-
nificantly shorter axon at 5 DIV. In contrast, consistent with
previous studies, complete inhibition of GSK-3 exerts a more
profound effect and neurons fail to extend an axon (Kim et al.,
2006; Garrido et al., 2007).
Our work identifies VCL as a critical mediator of axon growth
downstream of GSK-3/SRF signaling. VCL is amajor component
of cell-matrix adhesions and acts as a critical link between focal
adhesions and the actin cytoskeleton through direct interaction
with several binding partners, including talin, paxillin, and actin
(Ziegler et al., 2006; Humphries et al., 2007). Previous findings
have shown that -actin is a transcriptional target of SRF, sug-
gesting that neurite outgrowth deficits exhibited by SRF-deficient
neurons are likely the result of reduced actin levels (Ramanan et
al., 2005; Kno¨ll et al., 2006). However, expression of full-length
actin or various mutant forms of actin did not rescue growth
deficits in SRF-deficient hippocampal neurons (Kno¨ll et al., 2006;
Stern et al., 2009). Our findings suggest that it is likely that the
axonal defects observed in SRF-deficient neurons are not the
result of reduced actin expression, but rather the absence of pro-
teins, such asVCL,which are required formechanical coupling of
the actin cytoskeleton to focal adhesion sites. Therefore, restoring
VCL expression in SRF-deficient neuronsmay suffice to assemble
the actin cytoskeleton and provide the necessary driving force to
promote axonal growth.
We observed that, whereas VCL expression could rescue ax-
onal growth in SRF-deficient neurons, VCL ability to rescue ax-
onal growth in GSK-3-inhibited neurons was only partial,
suggesting the involvement of other GSK-3 targets and/or path-
ways. It has been shown that GSK-3 regulates axon growth by
regulating the activity of severalmicrotubule-associated proteins,
including MAP1B, CRMPs, and APC (Zhou et al., 2004; Goold
and Gordon-Weeks, 2005; Kim et al., 2006; Alabed et al., 2010).
MAP1B is activated by GSK-3 phosphorylation and contributes
to microtubule dynamics (Goold and Gordon-Weeks, 2005).
Therefore, in the absence of these critical GSK-3 targets, VCL
could promote axon growth in GSK-3 inhibited neurons only to
a limited extent.
GSK-3 inhibitory drugs are commonly used to treat neuro-
psychiatric and neurological disorders, including bipolar disor-
der, Parkinson’s disease, and Alzheimer’s disease (Bhat et al.,
2004; Cohen and Goedert, 2004). SRF has been shown to play a
critical role in immediate early gene expression, synaptic plastic-
ity, and learning and memory, whereas SRF cofactors MAL/
Figure10. Summarymodel.Model ofGSK-3-SRF signalingpathway in regulationof axongrowth. PhosphorylationbyGSK-3on
serine 224 results in the activation of SRF and subsequent recruitment of MKL-family cofactors. The SRF-MKL transcriptional
complex activates genes, such as VCL and MAP1B. MAP1B regulates microtubule dynamics, whereas VCL tethers F-actin to focal
adhesion junctions to promote neurite growth downstream of the GSK-3-SRF pathway. Absence of SRF or GSK-3 activity results in
inhibition or attenuation of neurite growth.
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MKLs are important for cerebellar long-termdepression (Ramanan
et al., 2005; Etkin et al., 2006; Smith-Hicks et al., 2010). It is likely
that targeting GSK-3 in the treatment of the above disorders
might also affect SRF-dependent neuronal development and
plasticity. Future studies will probe the effect of anti-GSK-3 ther-
apeutics on SRF transcriptional activity and its critical functions
in the nervous system.
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